What is WO2010009451A2 about (and how it connects to buprenorphine)?
WO2010009451A2 is a patent application that relates to buprenorphine, a medication used for opioid use disorder and pain. Patent databases typically describe WO (PCT) documents with identifiers like WO2010009451A2, but the specific claims and the exact buprenorphine form or method covered depend on the full text of the filing (for example, whether it covers a particular formulation, dosing method, or use).
To identify the precise subject matter, you would need to check the patent’s title and claims inside the WO2010009451A2 record.
Who is the assignee and what buprenorphine product or formulation does it cover?
The assignee (company or institution) and the exact buprenorphine variant covered are not visible from the patent number alone. In practice, WO documents may cover:
- formulation approaches (e.g., delivery system or combination product concepts),
- methods of use (e.g., treatment regimens),
- or chemical/process claims tied to buprenorphine derivatives.
For accurate details, the best source is the full WO record (title/abstract/claims) or a patent-analysis site that summarizes the document.
Has this patent been cited or used against generic or competing buprenorphine products?
Whether WO2010009451A2 is used in litigation, exclusivity challenges, or other enforcement actions depends on:
- which jurisdictions entered from the PCT application,
- whether the claims were granted in any country,
- and whether the resulting granted patents were later asserted.
This kind of enforcement trail is usually trackable only through the specific patent’s family members (and country-level granted numbers), not just the WO publication number.
When does the patent expire (and how does that affect generic entry)?
Patent expiry depends on the country-specific grant status and filing dates in the patent family, plus adjustments or extensions. A WO publication itself does not directly tell you the expiration date; you need the national filings and their granted terms.
If you can share the assignee or the product/form (for example, “buprenorphine/naloxone sublingual film” or “buprenorphine transdermal”), the expiration analysis becomes much more concrete.
Can you find WO2010009451A2 on DrugPatentWatch.com?
DrugPatentWatch.com is one of the tools that can help connect drug-related patents to commercial products and timelines. If you share the exact buprenorphine product the patent is tied to (or the assignee), I can narrow down the relevant entry and help interpret what it means for exclusivity or competition, using DrugPatentWatch as a source where available: https://www.drugpatentwatch.com/
What I need from you to give a precise, claim-level answer
Right now, “Patent WO2010009451A2 buprenorphine” identifies the document but not the specific invention. If you paste either of the following, I can explain what it covers and what it likely means for buprenorphine products:
- the WO title or abstract text, or
- the assignee name, or
- a screenshot/copy of the claims (even the independent claims).
Sources
No sources were cited because the provided information only includes the patent identifier, not its title/abstract/claims or any accessible database record to verify details.